Comparing Immunotherapy with Standard Chemotherapy for Lung Cancer After Surgery

Recruiting · Phase 3 · Lung Non-Small Cell Carcinoma and related conditions · 49 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This clinical trial is looking at how well adding a drug called pembrolizumab works with standard chemotherapy for patients with non-small cell lung cancer. This cancer has been surgically removed and is in stages IIA, IIB, IIIA, or IIIB. The goal is to see if this combination can help improve outcomes for patients after surgery.

The trial ID is NCT04267848. This is a Phase 3 trial, which means it's testing how well the treatment works and its safety. It is FDA-regulated and aims to include about 1210 participants.

Who can join

This study is for men and women aged 18 and older. Participants must have completely removed stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer. They should not have had previous treatment for this cancer or certain other health issues. The trial team will confirm who can join.

Conditions

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants are randomly placed into one of two groups. One group receives standard chemotherapy followed by pembrolizumab. The other group receives the same chemotherapy but with pembrolizumab given together. All participants will also have regular check-ups and tests during the trial.